

Methionine Synthase A2756G Polymorphism and Risk of Colorectal Adenoma and Cancer: Evidence Based on 27 Studies

Weixing Ding*³, Dong-lei Zhou³, Xun Jiang, Lie-sheng Lu*

Department of Gastroenterology, The Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China

Abstract

Methionine synthase (MTR), which plays a central role in maintaining adequate intracellular folate, methionine and normal homocysteine concentrations, was thought to be involved in the development of colorectal cancer (CRC) and colorectal adenoma (CRA) by affecting DNA methylation. However, studies on the association between MTR A2756G polymorphism and CRC/CRA remain conflicting. We conducted a meta-analysis of 27 studies, including 13465 cases and 20430 controls for CRC, and 4844 cases and 11743 controls for CRA. Potential sources of heterogeneity and publication bias were also systematically explored. Overall, the summary odds ratio of G variant for CRC was 1.03 (95% Cl: 0.96–1.09) and 1.05 (95% Cl: 0.99–1.12) for CRA. No significant results were observed in heterozygous and homozygous when compared with wild genotype for these polymorphisms. In the stratified analyses according to ethnicity, source of controls, sample size, sex, and tumor site, no evidence of any gene-disease association was obtained. Results from the meta-analysis of four studies on MTR stratified according to smoking and alcohol drinking status showed an increased CRC risk in heavy smokers (OR=2.06, 95% Cl: 1.32–3.20) and heavy drinkers (OR=2.00, 95% Cl: 1.28–3.09) for G allele carriers. This meta-analysis suggests that the MTR A2756G polymorphism is not associated with CRC/CRA susceptibility and that gene-environment interaction may exist.

Citation: Ding W, Zhou D-I, Jiang X, Lu L-s (2013) Methionine Synthase A2756G Polymorphism and Risk of Colorectal Adenoma and Cancer: Evidence Based on 27 Studies. PLoS ONE 8(4): e60508. doi:10.1371/journal.pone.0060508

Editor: Valli De Re, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Italy

Received December 30, 2012; Accepted February 26, 2013; Published April 9, 2013

Copyright: © 2013 Ding et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

- * E-mail: Weixing_Ding@163.com (WXD); liesheng_lu@163.com (LSL)
- 9 These authors contributed equally to this work.

Introduction

Colorectal cancer (CRC) is the third most common malignancy and the fourth most frequent cause of cancer deaths worldwide. More than one million new cases of CRC are diagnosed annually, and nearly 530,000 individuals die from CRC every year [1]. The etiology of CRC is complex and multifactorial. Hereditary syndromes, such as familial adenomatous polyposis and hereditary nonpolyposis CRC, account for <10% of all cases [2]. The majority of cases are thought to be caused by multiple factors, which include dietary and lifestyle habits and/or mild genetic predisposition [3]. Colorectal adenoma (CRA) is a recognized precursor of CRC based on epidemiologic, histological, and genetic studies demonstrating shared genetic alterations [4,5].

Low dietary intake or plasma level of folate has been found to increase the risk of colorectal cancer (CRC) in several case—control and cohort studies [6–8]. Folate is essential for the synthesis of S-adenosyl-methionine, which is the methyl donor required for various methylation reactions in cells [9]. Methylation of CpG sites inhibits DNA transcription and regulates gene expression and imbalanced DNA methylation is observed consistently in colonic neoplasia [10,11]. Accumulating evidence indicates that DNA methylation plays an important role in colorectal carcinogenesis [12].

Methionine synthase (MTR), on chromosome 1q43, encodes one of several key enzymes involved in the folate-mediated one-carbon metabolism. It catalyzes the methylation of homocysteine to methionine with simultaneous conversion of 5-methyl-tetrahydrofolate (5-methyl-THF) to tetrahydrofolate (THF). MTR is essential for the provision of S-adenosyl-methionine, the universal donor of methyl groups, as well as the provision of THF for use in nucleotide synthesis [13]. A common MTR variant consists of an A-to-G transition at base-pair 2756 and leads to a change from aspartic acid to glycine at codon 919 (D919G) [14]. Although the direct functional impact of this polymorphism has not been established, there is some evidence that this may be an activating polymorphism; in some studies, individuals with GG genotype have higher serum folate concentrations [15] and lower homocysteine concentrations [16,17].

An association between MTR A2756G polymorphism and genetic susceptibility to CRC and CRA has been widely documented but with inconsistent results. A single study may be too underpowered to detect a possible small effect of the polymorphism on CRC/CRA, especially when the sample size is relatively small. Besides, different types of study populations and study design may also contribute to the disparate findings. To help clarify the inconsistent findings, we conducted a comprehensive meta-analysis to quantify the overall risk of MTR A2756G polymorphism on developing CRC/CRA.

Materials and Methods

Literature Search Strategy

Eligible literatures published before the end of September 2012 were identified by a search of PUBMED, EMBASE, Web of science and CNKI (China National Knowledge Infrastructure) databases. Search term combinations were keywords relating to the methionine synthase (e.g., "methionine synthase", "MTR", "one-carbon metabolism") in combination with words related to CRC/CRA (e.g., "colorectal cancer", "colorectal tumor", "colorectal carcinoma", "rectal cancer", "colon cancer", and "colorectal adenoma") and "polymorphism" or "variation". All the searched studies were retrieved, and their references including relevant reviews were also hand-searched as well for other relevant studies. If more than one article were published using the same case series, only the study with largest sample size was selected.

Selection Criteria and Data Extraction

Studies included in the meta-analysis had to meet all the following criteria: (1) original papers containing independent data, (2) identification of CRC/CRA was confirmed pathologically or histologically, (3) sufficient data to calculate the odds ratio (OR) with its 95% confidence interval (CI) and P value, and (4) case—control or cohort studies and (5) genotype distribution of the control population must be in Hardy–Weinberg equilibrium.

Two investigators extracted data independently. When it came to conflicting evaluations, an agreement was reached after a discussion among all authors. Data were collected on the first author's surname, publication year, ethnicity of studied population (were categorized as "group), sample size, tumor site (rectal cancer vs. colon cancer), mean age of cases and controls, gender distribution in cases and controls, genotyping method, cigarette smoking status, alcohol consumption, confirmation of diagnosis, Hardy–Weinberg equilibrium (HWE) status, and genotype frequency in cases and controls. Where essential information was not presented in articles, every effort was made to contact the authors.

Statistical Methods

For the MTR gene, we estimated the risks of G allele of A2756G on CRC/CAR, compared with the A allele. Then, we estimated the risks of the heterozygous and homozygote genotypes on CRC/CAR, compared with the wild-type AA homozygote. The strength of the association between the MTR gene and CRC/ CRA risk was measured by ORs with 95% CIs. Cochran's chisquare Q test was used to calculate heterogeneity across individual studies. Random-effects and fixed-effect summary measures were calculated as inverse-variance-weighted average of the log OR [18]. The results of random-effects summary were reported in the text which takes into account the variation between studies. The significance of the overall OR was determined by the Z-test. Study size (\geq 500, and \leq 500 cases), source of controls (population versus hospital based), ethnicity (East Asian, Caucasian and others), sex, tumor sites (colon cancer versus rectum cancer) and types of end points (CRC versus CRA) were prespecified as characteristics for assessment of heterogeneity. Ethnic group was defined as East Asian (e.g., Chinese, Japanese, Korean), Caucasian (i.e., people of European origin), and Others ethnic populations (mixed or unknown populations). Subsequently, meta-regression was performed to further investigate potential sources of heterogeneityethnicity, sample size, age, and gender, specifying the method for estimating the between-study variance as restricted maximum likelihood. We assessed publication bias by using an ancillary procedure attributed to Egger et al. [19], which uses a linear regression approach to measure funnel plot asymmetry. To measure sensitivity analysis, each study was removed in turn from the total, and the remainder reanalyzed. This procedure was used to ensure that no individual study was entirely responsible for the combined results. All statistical analyses were carried out with the Stata software version 10.0 (Stata Corporation, College Station, TX). All P values are two-sided at the P=0.05 level.

Results

Characteristics of Studies

Figure S1 shows the study selection process. A total of 27 studies were retrieved based on the search criteria for CRC/CRA susceptibility related to the MTR A2756G polymorphism [20–46]. The main study characteristics were summarized in Table 1. There are 22 studies with 13465 patients and 20430 controls concerning CRC and 6 studies with 4844 patients and 11743 controls concerning CRA. The genotype distributions in the controls for all studies were consistent with HWE. Characteristics of studies included in the current meta-analysis are presented in Table 1.

Meta-analysis Results

As shown in Figure 1 and Table 2, no significant associations between the A2756G polymorphism of MTR and CRC or CRA susceptibility were found.

In the overall analysis, the 2756G was not significantly associated with elevated CRC risk. Using random effect model, the per-allele overall OR of the G variant for CRC was 1.03 (95% CI: 0.96-1.09, P = 0.42), with corresponding results for heterozygous and homozygous of 1.04 (95% CI: 0.96-1.12, P = 0.36) and 0.99 (95% CI: 0.85-1.16, P = 0.91), respectively. This analysis is based on pooling of data from a number of different ethnic populations. When stratifying for ethnicity, an OR of 0.99 (95% CI: 0.92-1.05, P = 0.66) and 1.17 (95% CI: 1.00-1.36, P = 0.06) resulted for G allele, among Caucasians and East Asians, respectively. By considering control source subgroups, the OR was 1.01 (95% CI: 0.94–1.08, P = 0.81) in population-based controls compared to 1.14 (95% CI: 0.97-1.33, P=0.12) in hospital controls. In the stratified analysis by sample size, no significant associations were found in large studies or small studies. In the subgroup analyses by tumor site, no significant associations were found for colon cancer and rectum cancer in all genetic modes. Subsidiary analyses of sex yielded a per-allele OR for male patients of 0.92 (95% CI: 0.82-1.02, P=0.12) and for female patients of 1.02 (95% CI: 0.86-1.22, P = 0.81). Similar results were also detected for heterozygous and homozygous. In a metaregression analysis, neither the ethnicity, sample size, nor age, sex correlated with the magnitude of the genetic effect (P>0.05 for all).

Data on genotypes of the MTR A2756G polymorphism among cases and controls stratified by smoking and alcohol consumption were available in four studies. Among heavy smokers (${\geq}40$ package/year) in all four studies, G allele carriers had a significantly increased CRC risk compared to the wild AA genotype with an OR of 2.06 (95% CI: 1.32–3.20; P=0.001, P heterogeneity=0.29). Using dominant genetic model, heavy alcohol drinkers (${\geq}50$ g ethanol/d on ${\geq}5$ day/week) with the G allele of A2756G variant had a significantly increased CRC risk with an OR of 2.00 (95% CI: 1.28–3.09; P=0.002, P heterogeneity=0.38).

Overall, there was no evidence for the association between MTR A2756G and CRA risk (G allele: OR = 1.05, 95% CI: 0.99-1.12; heterozygous: OR = 1.03, 95% CI: 0.94-1.12; homozygous: OR = 1.16, 95% CI: 0.94-1.43). No significant heterogeneity was found for included studies (P>0.05). Analysis restricted to the 4

Table 1. Characteristics of the studies included in the meta-analysis.

Study	Year	Ethnicity C	ases	Controls source	Genotyping method	No. of cases/controls	Mean age of cases/controls	Sex distribution in cases/ controls (male %)
Ma [20]	1999	American CI	RC	Population	RFLP	356/476	NA/NA	100/100
Matsuo [21]	2002	Japanese CI	RC	Hospital	RFLP	142/241	NA/NA	58.9/49.0
Le Marchand [22]	2002	American CI	RC	Population	RFLP	539/652	66.0/67.0	60.8/57.9
Ulvik [23]	2004	Norwegian CI	RC	Population	Taqman	2168/2192	NA/NA	63.5/63.5
Ulrich [24]	2005	American CI	RC	Population	Taqman	1600/1962	64.9/65.0	56.0/53.0
Matsuo [25]	2005	Japanese CI	RC	Hospital	RFLP	257/771	58.8/59.0	63.0/63.0
Chen [26]	2006	Chinese CI	RC	Population	RFLP	199/413	62.5/61.9	50.8/51.7
Koushik [27]	2006	American CI	RC	Population	Taqman	363/804	68.2/68.0	47.6/42.0
Curtin [28]	2007	American CI	:RC	Population	Taqman	916/1974	NA/NA	NA/NA
Steck [29]	2008	American CI	RC	Population	Taqman	546/855	63.8/65.9	NA/NA
Zhang [30]	2008	Chinese CI	RC	Hospital	RFLP	298/300	57.7/57.6	56.3/56.7
Guerreiro [31]	2008	Portuguese CI	RC	Population	Taqman	196/200	64.2/62.2	53.1/53.0
Theodoratou [32]	2008	Scottish CI	RC	Population	Array	999/1010	62.3/62.7	57.3/56.9
Zhang [33]	2009	Chinese CI	RC	Hospital	RFLP	476/835	54.3/52.0	57.1/55.1
de Vogel [34]	2009	Dutch CI	:RC	Population	SNaPShot	696/1805	NA/NA	55.0/50.2
Levine [35]	2010	American CI	RC	Population	iPLEX	1806/2879	53.5/54.0	51.3/44.4
Eussen [36]	2010	European CI	RC	Population	Mass spectrometry	1329/2364	58.9/58.7	51.0/53.0
Guimarães [37]	2011	Brazilian CI	RC	Population	RFLP	113/188	59.0/54.0	53.1/64.4
Jokić [38]	2011	Croatian CI	RC	Population	Taqman	300/300	62.2/61.4	54.0/50.6
Kim [39]	2011	Korean CI	RC	Hospital	RFLP	67/53	61.8/58.7	52.2/43.4
Martinelli [40]	2012	Italian CI	RC	Population	RFLP	71/80	69.0/58.0	59.2/53.8
Pufulete [41]	2003	British CI	RC, CRA	Hospital	RFLP	63/76	68.9/58.0	46.0/45.0
Goode [42]	2004	American CI	:RA	Population	Taqman	513/609	NA/NA	63.0/38.8
Hazra [43]	2007	American CI	RA	Population	Taqman	529/532	NA/NA	0/0
Yamaji [44]	2009	Japanese CI	:RA	Population	Taqman	723/607	61.0/60.0	67.5/65.4
de Vogel [45]	2011	Norwegian CI	RA	Population	Mass spectrometry	1713/8355	56.9/56.1	60.6/47.0
Han [46]	2012	American CI	:RA	Population	Taqman	1331/1501	NA/NA	NA/NA

doi:10.1371/journal.pone.0060508.t001

studies with at least 500 cases, yielded an OR of 1.05 (95% CI: 0.99-1.12) for G allele.

Sensitivity Analyses and Publication Bias

A single study involved in the meta-analysis was deleted each time to reflect the inuence of the individual data-set to the pooled OR, and the corresponding pooled OR was not materially altered, suggesting that the results of this meta-analysis are stable (data not shown). As shown in Figure S2, the shape of the funnel plot seemed symmetrical, suggesting no publication bias among the studies included. Egger's test also indicated no evidence of publication bias in relation to allele or genotype comparison (P>0.05, for all).

Discussion

Genes in the one-carbon metabolic pathway may modulate risk of CRC and CRA by influencing methyl group availability for DNA methylation reactions or nucleotide synthesis [11,28,34,47,48]. It is currently believed that perhaps up to 30% of colorectal cancer cancers are characterized by this CpG island methylator phenotype (CIMP), in which numerous CpG islands

are methylated and tumor suppressor genes such as the cell-cycle regulator, p16, are inactivated [49,50]. A recent study showed that 60% of colorectal adenomas are abnormally methylated on at least one locus. Furthermore, CpG island methylation phenotype has been demonstrated in large colorectal adenomas and in adenomas with tubular or villous histology [51,52]. This is the most comprehensive meta-analysis examined the A2756G polymorphism of MTR and the relationship to susceptibility for CRC and CRA. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 26 studies which provided 18309 cases and 32034 controls.

In this large-scale meta-analysis, the combined evidence suggested that MTR A2756G polymorphism did not contribute to the development of CRC or CRA. For the subgroup analysis based on ethnicity, sample size, source of controls, tumor site, and sex we were unable to observe any effect modification, which is in line with the pooled analysis. Data from the studies did not exhibit statistically significant heterogeneity in the majority of contrasts. There are some possible reasons for the inconsistent results in early reports. Firstly, ethnic differences may attribute to these different results, since the distributions of the A2756G polymorphism were




Figure 1. Forest plot from the meta-analysis of MTR A2756G polymorphism and CRC/CRA risk. doi:10.1371/journal.pone.0060508.g001

different between various ethnic populations. In fact, the distribution of the less common G allele varies extensively between different races, with a prevalence of $\sim 14\%$ among East Asians, $\sim 20\%$ among Caucasians. On the other hand, study design or small sample size or some environmental factors may affect the results. Most of these studies did not consider most of the important environmental factors. It is possible that variation at this locus has modest effects on CRC/CRA, but environmental factors may predominate in the progress of CRC/CRA, and mask the

effects of this variation. Specific environmental factors like lifestyle and cigarette smoking have already been well studied in recent decades [53,54]. The unconsidered factors mixed together may cover the role of MTR polymorphism. Thus, even if the variation has a causal effect on CRC, it may take a long time to be observed. CRC/CRA is a complex disease, and both environmental and genetic factors are involved in the development of the disease. Thus, the effect of single genetic factor on the risk of CRC/CRA may be more pronounced in the presence of other common

Table 2. Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.

Sub-group analysis	No. of cases/ controls	G Allele			Heterozygous			Homozygous		
		OR (95%CI)	P(Z)	P(Q)	OR (95%CI)	P(Z)	P(Q)	OR (95%CI)	P(Z)	P(Q)
Colorectal cancer	13465/20430	1.03 (0.96–1.09)	0.42	0.008	1.04 (0.96–1.12)	0.36	0.03	0.99 (0.85–1.16)	0.91	0.19
Ethnicity										
East Asian	1754/3007	1.17 (1.00–1.36)	0.06	0.14	1.19 (0.96–1.48)	0.11	0.05	1.22 (0.84–1.78)	0.30	0.78
Caucasian	11396/17014	0.99 (0.92–1.05)	0.66	0.05	0.99 (0.92-1.07)	0.82	0.20	0.93 (0.77–1.13)	0.46	0.09
Others	315/409		0.20	0.37	1.13 (0.82–1.55)	0.46	0.40	1.57 (0.78–3.19)	0.21	0.69
Sample size										
Large studies	9514/14186	0.99 (0.92–1.08)	0.90	0.02	0.99 (0.90-1.10)	0.90	0.03	0.95 (0.73-1.25)	0.73	0.008
Small studies	3951/6244	1.06 (0.96–1.16)	0.28	0.08	1.08 (0.97-1.20)	0.18	0.16	1.09 (0.86–1.37)	0.48	0.79
Controls source										
Population	12197/18154	1.01 (0.94–1.08)	0.81	0.01	1.02 (0.94–1.10)	0.71	0.05	0.96 (0.81–1.14)	0.67	0.16
Hospital	1268/2276	1.14 (0.97–1.33)	0.12	0.29	1.15 (0.94–1.40)	0.17	0.25	1.27 (0.82–1.97)	0.28	0.50
Tumor sites										
Colon cancer	1988/2779	1.06 (0.88–1.28)	0.56	0.10	1.09 (0.88-1.35)	0.41	0.15	0.78 (0.56–1.09)	0.15	0.62
Rectum cancer	1331/2162	1.24 (0.88–1.74)	0.21	0.002	1.32 (0.93–1.89)	0.12	0.008	0.77 (0.48–1.23)	0.28	0.58
Sex										
Male	3004/3810	0.92 (0.82–1.02)	0.12	0.23	0.95 (0.81-1.11)	0.53	0.13	0.75 (0.51–1.10)	0.14	0.12
Female	1796/2623	1.02 (0.86–1.22)	0.81	0.07	1.01 (0.89–1.16)	0.86	0.59	1.03 (0.61–1.74)	0.92	0.05
Colorectal adenoma	4844/11743	1.05 (0.99–1.12)	0.11	0.89	1.03 (0.94–1.12)	0.57	0.80	1.16 (0.94–1.43)	0.18	0.52
Caucasian only	4121/11073	1.06 (0.99–1.13)	0.11	0.83	1.02 (0.92–1.12)	0.76	0.73	1.21 (0.97–1.52)	0.09	0.60
Large studies only	4809/11667	1.05 (0.99–1.12)	0.12	0.82	1.02 (0.93–1.12)	0.64	0.85	1.17 (0.93–1.46)	0.18	0.37
Total	18309/32173	1.03 (0.98-1.09)	0.19	0.03	1.03 (0.97-1.10)	0.28	0.08	1.03 (0.90-1.17)	0.68	0.20

doi:10.1371/journal.pone.0060508.t002

genetic or environmental risk factors such as smoking, red meat consumption, and alcohol abuse.

Alcohol consumption has a hazardous effect on folate metabolism, which is closely related to the DNA methylation pathway. Unfortunately, almost all the studies failed to explore the interaction between MTR genotype and alcohol drinking habits. This was probably due to the low statistical power of the individual studies to detect interactions. Our results show a significant association among heavy drinkers subgroup between MTR A2756G polymorphism and CRC risk. Alcohol drinking inhibits folate absorption from the intestine, interrupts folate release from the liver, and promotes urinary excretion of folate from the body [55], all of which result in reduced levels of serum folate [56], of which 5-methyl-tetrahydrofolate is the predominant component. The provision of 5-methyltetrahydrofolate is crucial for methionine synthase to catalyze the remethylation of homocysteine to methionine. In addition, alcohol intake can directly interfere with the enzymatic activity of methionine synthase [57]. Further, the influence of alcohol intake may vary among individuals with different genetic susceptibility. Our observation of an interaction between MTR A2756G and alcohol consumption suggests that the DNA methylation pathway is implicated in the development of colorectal cancer. Tobacco smoking is an established risk factor for many cancers. By pooling the collected data on smoking status and MTR genotypes, a statistically significant 2.00 fold increased risk for CRC appeared for individuals carrying the risk G allele in comparison with individuals with the wild AA genotype. This result suggests that in the presence of both of the two risk factors, an important number of CRC cases would occur.

Some limitations should be considered when interpreting our results, in addition to those inherited from the meta-analysis. Firstly, the subgroup meta-analyses considering interactions between MTR genotype and cigarette smoking, as well as alcohol drinking, were performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be over inated. Secondly, our results were based on unadjusted estimates, whereas a more precise analysis could be conducted if all individual raw data were available, which would allow for the adjustment by other co-variables including age, sex, drinking status, cigarette consumption, and other lifestyle factors. Ideally we would like to pool individual-level data. However this is not possible for the present study. Further large and well-designed studies need to be performed to further confirm our results. Thirdly, because only published studies were retrieved in the meta-analysis, publication bias might be possible, even though the statistical test did not show it.

In conclusion, our meta-analysis suggests that there is no association between MTR A2756G polymorphism and CRC/CRA. However, the A2756G polymorphism of MTR may modulate the tobacco-related as well as alcohol-related pathogenesis of CRC. For future association studies, strict selection of patients and larger sample size of different ethnic populations are required. Moreover, gene—gene and gene—environment interactions should also be considered.

Supporting Information

Figure S1 Study selection process. (TIF)

Figure S2 Funnel plot of association between MTR A2756G polymorphism and CRC/CRA overall individuals.

(TIF)

Checklist S1 PRISMA Checklist.

(DOC)

References

- Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
- Desai TK, Barkel D (2008) Syndromic colon cancer: lynch syndrome and familial adenomatous polyposis. Gastroenterol Clin North Am 37: 47–72.
- de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, et al. (2002) Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11: 1332–1352.
- Cotton S, Sharp L, Little J (1996) The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. Crit Rev Oncog 7: 293–342.
- Mulder JW, Offerhaus GJ, de Feyter EP, Floyd JJ, Kern SE, et al. (1992) The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 141: 797– 804
- Tseng M, Murray SC, Kupper LL, Sandler RS (1996) Micronutrients and the risk of colorectal adenomas. Am J Epidemiol 144: 1005–1014.
- Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, et al. (1998) Multivitamin use, folate and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129: 517–524.
- Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ (2005) Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 113: 825– 828.
- Wasson GR, McGlynn AP, McNulty H, O'Reilly SL, McKelvey-Martin VJ, et al. (2006) Global DNA and p53 region-specific hypomethylation in human colorectalic cells is induced by folate depletion and reversed by folate supplementation. J Nutr 136: 2748–2753.
- Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP (1985) Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187– 190.
- Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, et al. (1992) Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 89: 1929–1933.
- Pufulete M, Emery PW, Sanders TA (2003) Folate, DNA methylation and colorectal cancer. Proc Nutr Soc 62: 437

 –445.
- 13. Banerjee RV, Matthews RG (1990) Cobalamin-dependent methionine synthase. FASEB J 4: 1450–1459.
- Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, et al. (1996) A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 56: 4862–4864.
- Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, et al. (2001) Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 154: 667, 679
- Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, et al. (2001) Geneenvironment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 85: 67–74.
- 17. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, et al. (2000) Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 149: 131–137.
- DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
- Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
- Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, et al. (1999) A
 polymorphism of the methionine synthase gene: association with plasma folate,
 vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol
 Biomarkers Prev 8: 825–829.
- Matsuo K, Hamajima N, Hirai T, Kato T, Inoue M, et al. (2002) Methionine Synthase Reductase Gene A66G Polymorphism is Associated with Risk of Colorectal Cancer. Asian Pac J Cancer Prev 3: 353–359.
- Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, et al. (2002)
 B-vitamin intake, metabolic genes, and colorectal cancer risk (United States).
 Cancer Causes Control 13: 239–248.
- 23. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, et al. (2004) Colorectal cancer and the methylenetetrahydrofolate reductase 677C -> T and methionine synthase 2756A -> G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 13: 2175–2180.
- Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, et al. (2005) Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14: 2509–2516.

Author Contributions

Conceived and designed the experiments: WXD LSL. Performed the experiments: WXD DLZ XJ. Analyzed the data: WXD DLZ XJ. Contributed reagents/materials/analysis tools: WXD DLZ XJ LSL. Wrote the paper: WXD DLZ LSL.

- Matsuo K, Ito H, Wakai K, Hirose K, Saito T, et al. (2005) One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis 26: 2164–2171.
- Chen K, Song L, Jin MJ, Fan CH, Jiang QT, et al. (2006) Association between genetic polymorphisms in folate metabolic enzyme genes and colorectal cancer: a nested case-control study. Zhonghua Zhong Liu Za Zhi 28: 429–432.
- Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, et al. (2006) Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 15: 2408–2417.
- Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, et al. (2007) Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis 28: 1672–1679.
- Steck SE, Keku T, Butler LM, Galanko J, Massa B, et al. (2008) Polymorphisms in Methionine Synthase, Methionine Synthase Reductase and Serine Hydroxymethyltransferase, Folate and Alcohol Intake, and Colon Cancer Risk. J Nutrigenet Nutrigenomics 1: 196–204.
- Zhang YL, Yuan XY, Zhang Z, Yang H, Zhou YH, et al. (2008) Relationship of genetic polymorphisms in methylenetetrahydrofoIate reductase and alcohol drinking with the risk of colorectal cancer. Zhonghua Zhong Liu Fang Zhi Za Zhi 15: 1298–1301.
- 31. Guerreiro CS, Carmona B, Gonçalves S, Carolino E, Fidalgo P, et al. (2008) Risk of colorectal cancer associated with the C677T polymorphism in 5,10methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. Am J Clin Nutr 88: 1413–1418.
- Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, et al. (2008) Dietary vitamin B6 intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 17: 171–182.
- Zhang YL, Yuan XY, Zhang Z, Yang H, Zhou YH, et al. (2009) Relationship of genetic polymorphisms in thymidylate synthase and alcohol drinking with risk of colorectal cancer. Zhonghua Zhong Liu Fang Zhi Za Zhi 16: 568–572.
- 34. de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, (2009) Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 18: 3086–3096.
- Levine AJ, Figueiredo JC, Lee W, Conti DV, Kennedy K, et al. (2010) A Candidate Gene Study of Folate-Associated One Carbon Metabolism Genes and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev 19: 1812– 1991
- Eussen SJ, Vollset SE, Igland J, Meyer K, Fredriksen A, et al. (2010) Plasma Folate, Related Genetic Variants, and Colorectal Cancer Risk in EPIC. Cancer Epidemiol Biomarkers Prev 19: 1328–1340.
- Guimarães JL, Ayrizono Mde L, Coy CS, Lima CS (2011) Gene polymorphisms involved in folate and methionine metabolism and increased risk of sporadic colorectal adenocarcinoma. Tumour Biol 32: 853–861.
- 38. Jokić M, Brčić-Kostić K, Stefulj J, Catela Ivković T, Božo L, et al. (2011) Association of MTHFR, MTR, MTRR, RFC1, and DHFR Gene Polymorphisms with Susceptibility to Sporadic Colon Cancer. DNA Cell Biol 30: 771–776.
- Kim JW, Park HM, Choi YK, Chong SY, Oh D, et al. (2011) Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep 25: 167–172.
- Martinelli M, Scapoli L, Mattei G, Ugolini G, Montroni I, et al. (2012) A candidate gene study of one-carbon metabolism pathway genes and colorectal cancer risk. Br J Nutr 16: 1–6.
- Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, et al. (2003) Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 124: 1240–1248.
- Goode EL, Potter JD, Bigler J, Ulrich CM (2004) Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 13: 157–162.
- Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, et al. (2007) Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. Carcinogenesis 28: 1510– 1519.
- 44. Yamaji T, Iwasaki M, Sasazuki S, Sakamoto H, Yoshida T, et al. (2009) Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 18: 267–274.
- de Vogel S, Schneede J, Ueland PM, Vollset SE, Meyer K (2011) Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiol Biomarkers Prev 20: 1726–1735.

- 46. Han SS, Sue LY, Berndt SI, Selhub J, Burdette LA, et al. (2012) Associations between Genes in the One-Carbon Metabolism Pathway and Advanced Colorectal Adenoma Risk in Individuals with Low Folate Intake. Cancer Epidemiol Biomarkers Prev 21: 417–427.
- Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, et al. (2004) Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer 110: 617–620.
- Friso S, Choi SW (2005) Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab 6: 37–46.
- van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51: 797–802.
- Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376–1387.
- Kim HC, Roh SA, Ga IH, Kim JS, Yu CS, et al. (2005) CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol 20: 1920–1926.

- Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. (2006) CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45: 781–789
- Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, et al. (2005) Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Mol Carcinog 44: 21–30.
- Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sébille V, et al. (2007) Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 16: 1460–1467.
- Hillman RS, Steinberg SE (1982) The effects of alcohol on folate metabolism. Annu Rev Med 33: 345–354.
- Eichner ER, Hillman RS (1973) Effect of alcohol on serum folate level. J Clin Invest 52: 584–591.
- Giovannucci E (2004) Alcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies. J Nutr 134: 2475–2481S.